Foundation Medicine said this week at the JP Morgan Healthcare Conference in San Francisco that it received orders for 9,000 of its FoundationOne next-generation sequencing cancer tests in 2013.

The company targets its test to both oncologists to help guide treatment of patients and also to pharmaceutical companies. During a presentation at the conference, CEO Michael Pellini highlighted the test's benefits to both groups and gave an overview of how the company plans to move forward in 2014 and the years ahead.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.